lung cancer

News

AZ, Daiichi eye December verdict for TROP2 ADC

The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan as a therapy for lung cancer, the second drug in their antibody-drug conjugate (ADC

News

Tagrisso-chemo cleared in US as 1st-line lung cancer therapy

AstraZeneca’s Tagrisso can be used alongside chemotherapy as a frontline therapy for EGFR-positive non-small cell lung cancer (NSCLC), according to the FDA, consolidating

News

Then there were two: ArriVent set to list after $175m IPO

ArriVent BioPharma was beaten to the first biotech initial public offering of the year when CG Oncology made its debut on the Nasdaq yesterday, but is due to start trading

News

BMS gets US approval for ROS1 lung cancer drug Augtyro

Bristol-Myers Squibb has secured FDA approval for Augtyro, a lung cancer therapy it acquired as part of its $4.1 billion takeover of Turning Point Therapeutics last year t

News

AZ’s Tagrisso plus chemo get fast FDA review for lung cancer

AstraZeneca will hear back from the FDA in the first quarter of next year about its recent filing of Tagrisso in combination with chemotherapy as a first-line treatment fo

Patients